Compare Sibanye Stillwater Ltd (SBSW) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sibanye Stillwater Ltd vs TransMedics Group Inc — how do they compare? Sibanye Stillwater Ltd trades at $10 (market cap $6.88B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Sibanye Stillwater Ltd is far larger — about 2.5× TransMedics Group Inc's market cap, and Sibanye Stillwater Ltd pays a 8.17% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sibanye Stillwater Ltd for 51 Days and TransMedics Group Inc for 24 Days on average.
| SBSW | TMDX | |
|---|---|---|
Market Cap | $6.88B | $2.74B |
Volume | 4,474,536 | 949,331 |
Sector | Basic Materials | Health |
52-Week High | $21.12 | $150.42 |
52-Week Low | $8.00 | $61.99 |
Typical Hold Time | 51 Days | 24 Days |
Enterprise Value | $7.78B | $3.13B |
Dividend Yield | 8.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SBSW trades at $10.00, up 3.31% with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company shows strong revenue growth to $129.68B in 2025 and improved cash flow, though net income remains negative. Analyst consensus is moderately bullish with a $14.25 price target, supported by recent institutional buying activity and positive coverage of H1 2026 results.
The outlook suggests potential upside based on valuation metrics (P/E 8.12, P/S 0.7) and projected 2026 profitability, but risks include persistent negative earnings, high debt levels, and commodity price sensitivity. Investors should weigh the attractive valuation against operational execution challenges in the mining sector.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
